Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer

19962,869 citationsJournal Articlebronze Open Access

Authors

William P. McGuire · Memorial Sloan Kettering Cancer Center

William J. Hoskins · Cornell University

Mark F. Brady

Paul R. Kucera · Oregon Health & Science University

Edward E. Partridge · University of Alabama at Birmingham

Katherine Y. Look · Indiana University – Purdue University Indianapolis

Daniel L. Clarke‐Pearson

Martin Davidson

Abstract

Incorporating paclitaxel into first-line therapy improves the duration of progression-free survival and of overall survival in women with incompletely resected stage III and stage IV ovarian cancer.

Topics & Keywords

Cancer Treatment and Pharmacology Chemotherapy-induced cardiotoxicity and mitigation Chemotherapy-induced organ toxicity mitigation

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 334, Issue 1, pp. 1-6

DOI: 10.1056/nejm199601043340101

Field-Weighted Citation Impact: 72.85